Quidel Stock

Quidel EBITDA per Employee

The EBITDA per Employee of Quidel (QDEL) as of Aug 5, 2026 is -584,000.00 USD. In the previous year, EBITDA per Employee was -1.39 M USD — a change of -58.03% (higher).

EBITDA per Employee

-584,000.00USD

YoY

-58.03%

Last updated:

EBITDA per Employee of Quidel is 2026 -584,000.00 USD. EBITDA per Employee of Quidel was 2025 -1.39 M USD. It decreases by -58.03% higher compared to the previous year.
Access this data via the Eulerpool API

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

EBITDA per Employee of Quidel is -584,000.00 USD in 2026.

EBITDA per Employee of Quidel changed from -1.39 M USD to -584,000.00 USD, representing a -58.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Quidel since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Quidel historically and in real time.

Access this data via the Eulerpool API

Workforce — Quidel

All Key Metrics — Quidel